GSK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
GSK plc is not a strong buy at the moment for a beginner investor with a long-term horizon. While the company shows solid financial performance and recent acquisitions that could bolster its pipeline, the technical indicators and trading sentiment suggest a neutral to slightly bearish short-term outlook. Additionally, analysts' ratings are mixed, with some concerns about mid-term growth challenges. Given the user's impatience and unwillingness to wait for optimal entry points, it would be prudent to hold off on investing in GSK for now.
The MACD is negatively expanding, indicating bearish momentum. RSI is neutral at 39.511, and the stock is trading near its support level of 58.385, suggesting limited immediate upside. While moving averages are bullish, the overall technical picture leans neutral to bearish.
Revenue, net income, and EPS showed significant YoY growth in Q4
Recent acquisitions, such as 35Pharma, enhance the company's pipeline in pulmonary hypertension.
ViiV Healthcare's VH184 shows promise for long-acting HIV treatment.
Regular market change of -2.47% and a pre-market drop of -0.74% indicate weak short-term sentiment.
Analysts' ratings are mixed, with some firms maintaining Neutral or Underweight ratings due to mid-term growth challenges and loss of exclusivities.
The FDA's safety reassessment of Butylated Hydroxyanisole (BHA) could pose regulatory risks.
In Q4 2025, revenue increased by 10.24% YoY, net income surged by 59.51% YoY, EPS grew by 61.54% YoY, and gross margin improved to 69.7%, up 1.12% YoY. This indicates strong financial growth and operational efficiency.
Analysts' ratings are mixed. Barclays raised its price target but maintains an Underweight rating. TD Cowen and BofA raised their price targets, citing confidence in the company's R&D and product pipeline. However, concerns about mid-term growth challenges and loss of exclusivities persist, as noted by Citi and Barclays.
